{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-24-000152","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2024-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.798672+00:00","generated_at":"2026-05-31T08:26:36.141309+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Emergent BioSciences closes sale of Baltimore-Camden facility to Bora for $30M","bullets":["Sold drug product facility in Baltimore-Camden to affiliate of Bora Pharmaceuticals (TWSE:6472) for ~$30M at closing.","Bora acquired all assets, equipment, and workforce associated with the 87,000 sq ft facility.","CEO Joe Papa says sale is a step in multi-year plan to stabilize, improve profitability, and reduce debt.","Truist Securities and Covington & Burling advised Emergent on the transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-24-000152","json":"https://secwatch.observer/filing/0001367644-24-000152.json","markdown":"https://secwatch.observer/filing/0001367644-24-000152.md","text":"https://secwatch.observer/filing/0001367644-24-000152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000152/0001367644-24-000152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000152/ebs-20240820.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:26:36.141309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}